Table 2 Variables associated with adiponectin on univariate linear regression analysis in the LANDMARK 2 population
Univariate Analysis | |||
|---|---|---|---|
Variable | β | P | 95% CI |
Sex | 3.24 | 0.01 | 7.71-5.71 |
Body mass index (kg/m2) | -0.30 | 0.009 | -0.53 to -0.08 |
Abnormal glucose tolerance | -3.67 | 0.008 | 0.95-6.40 |
Metabolic syndrome | -2.47 | 0.047 | -4.91 to -0.03 |
Combined cardiovascular events | -2.03 | 0.16 | -4.84 to 0.79 |
Waist hip ratio (cm) | -21.48 | 0.001 | -33.06 to -9.90 |
Log fasting glucose (mmol/L) | -4.55 | 0.04 | -8.60 to -0.49 |
Log triglyceride (mmol/L) | -6.10 | <0.001 | -8.63 to -3.56 |
Log HDL (mmol/L) | 11.05 | <0.001 | 7.23 to 14.88 |
VLDL (mmol/L) | -5.99 | 0.001 | -9.48 to -2.49 |
Apolipoprotein a (g/L) | 10.93 | <0.001 | 5.63 to 16.23 |
C-reactive protein (mg/L) | |||
0.9-2 | ref | ref | ref |
2.1-4.7 | -1.15 | 0.44 | -4.07 to 1.77 |
4.8-84 | -4.03 | 0.007 | -6.95 to -1.11 |
Urinary PCR (mg/L) | |||
5-14 | ref | ref | ref |
15-35 | 0.18 | 0.91 | -3.10 to 3.47 |
36-1000 | -2.27 | 0.15 | -5.40 to 0.85 |
GFR (mls/min/1.73 m2) | -0.45 | 0.18 | -0.11 to 0.02 |
ACE inhibitor (mg/day) | -2.12 | 0.1 | -4.70 to 0.45 |
ARB (mg/day) | 2.70 | 0.1 | -0.51 to 5.90 |